

✓  
Please cancel claims 30-34, without prejudice or disclaimer.

1. (Previously Amended) A method for producing a virus and/or viral proteins other than adenovirus or adenoviral proteins for use as a vaccine, said method comprising:  
providing a cell with at least a sequence encoding at least one gene product of the E1 gene or a functional derivative thereof of an adenovirus,  
providing said cell with a nucleic acid encoding said non-adenoviral virus and/or said non-adenoviral viral proteins,  
culturing said cell in a suitable medium and allowing for expression of said non-adenoviral virus and/or said non-adenoviral viral proteins, and  
harvesting said non-adenoviral virus and/or non-adenoviral viral proteins from said suitable medium and/or said cell.
2. (Previously Amended) The method according to claim 1, wherein said cell is a human primary cell.
3. (Previously Amended) The method according to claim 1 wherein said human primary cell is immortalized by a gene product of the E1 gene.
4. (Previously Amended) The method according to claim 2 wherein said cell is derived from a human embryonic retinoblast.
5. (Previously Amended) The method according to claim 2 wherein said sequence encoding at least one gene product of the E1 gene is present in the genome of said human primary cell.
6. (Previously Amended) The method according to claim 1 wherein said cell does not produce adenoviral structural proteins.

7. (Previously Amended) The method according to claim 2 wherein said cell further comprises a sequence encoding E2A or a functional derivative or analogue or fragment thereof.

8. (Previously Amended) The method according to claim 7 wherein said sequence encoding E2A or a functional derivative or analogue or fragment thereof, is present in the genome of said human primary cell.

9. (Previously Amended) The method according to claim 7 wherein said E2A encoding sequence encodes the temperature sensitive mutant E2A.

10. (Previously Amended) The method according to claim 2 wherein said human primary cell comprises no other adenoviral sequences

11. (Previously Amended) The method according to claim 2 wherein said human primary cell is grown in suspension.

12. (Previously Amended) The method according to claim 2 wherein said human primary cell is cultured in the absence of serum.

13. (Previously Amended) The method according to claim 2 wherein said human cell is PER.C6 as deposited under ECACC no. 96022940 or derivative thereof.

14. (Previously Amended) The method according to claim 1 wherein said virus and/or said viral proteins comprise a protein that undergoes post-translational and/or peritranslational modifications.

15. (Previously Amended) The method according to claim 14 wherein said post-translational and/or peritranslational modifications comprise glycosylation of a viral protein.

16. (Previously Amended) The method according to any one of the foregoing claims wherein said viral proteins comprise at least one of an Influenza virus neuramidase or a hemagglutinin.

17. (Previously Amended) The method according to claim 1 wherein said non-adenoviral virus is selected from the group of non-adenoviral viruses consisting of enterovirus, rhinovirus, aphthovirus, poliomyelitis virus herpesvirus, herpes simplex virus, pseudorabies virus, bovine herpes virus, orthomyxovirus, influenza virus, paramyxovirus, New Castle disease virus, respiratory syncytio virus, mumps virus, measles virus, retrovirus, human immunodeficiency virus, parvovirus, papavovirus, rotavirus, coronavirus, transmissible gastroenteritis virus, flavivirus, tick-borne encephalitis virus, yellow fever virus, togavirus, rubella virus, Eastern equine encephalomyelitis virus, Western equine encephalomyelitis virus, Venezuelan equine encephalomyelitis virus, hepatitis causing virus, hepatitis A virus, hepatitis B virus, pestivirus, hog cholera virus, rhabdovirus, and rabies virus.

25. (Previously Amended) An improvement in a process for producing a non-adenoviral virus or viral protein for use in a vaccine for use in a human subject, said process being of the type wherein a cell line is infected with a virus, the improvement comprising: using, as the cell line in the process, a human cell having a sequence encoding at least one E1 protein of an adenovirus or a functional derivative, homologue or fragment thereof in its genome, which human cell does not produce structural adenoviral proteins.

26. (Previously Amended) The improvement of claim 25, wherein said human cell is derived from a primary cell.

27. (Previously Amended) The improvement of claim 25, wherein said human cell is a PER.C6 cell or a derivative thereof.

28. (Previously Amended) The improvement of claim 25 wherein said human cell further comprises a sequence encoding adenoviral E2A or a functional derivative or analogue or fragment thereof in its genome.

29. (Previously Amended) The improvement of claim 28, wherein said adenoviral E2A is temperature sensitive.

30. (Previously Amended) A non-adenoviral virus or non-adenoviral viral protein for use a vaccine produced by the process of claim 1, said virus or said viral being free of any non-human mammalian proteinaceous material.

31. (Previously Amended) A human cell having a sequence encoding at least one E1 protein of an adenovirus or a functional derivative, homologue or fragment thereof in its genome, which human cell does not produce structural adenoviral proteins, and said human cell further having a nucleic acid encoding a virus or at least one non-adenoviral viral protein.

32. (Previously Amended) The human cell of claim 31 which is derived from PER.C6 as deposited under ECACC no. 96022940.

33. (Previously Amended) The human cell of claim 31, which further comprises a sequence encoding adenoviral E2A or a functional derivative or analogue or fragment thereof in the human cell's genome.

34. (Previously Amended) The human cell of claim 33, wherein said adenoviral E2A is temperature sensitive.

35. The method according to claim 2 wherein said primary cell is immortalized by a gene product of said E1 gene.

✓  
Please add the following new claims:

---

36. (New) The method according to claim 1, wherein harvesting said non-adenoviral virus and/or non-adenoviral viral proteins comprises recovery of said virus and/or viral proteins using ion-exchange chromatography.

B1  
37. (New) The method according to claim 1, wherein the at least one gene product of the E1 gene comprises a plasmid containing an Ad serotype 5 (Ad5) E1A- and E1B-coding sequence (Ad5 nucleotides 459-3510).

38. (New) The method according to claim 1, wherein said viral protein is selected from the group of Influenza surface antigens consisting of surface glycoproteins, hemagglutinin and neuraminidase.

---